Key result
Two ADIPOR1 SNPs were associated with an ~18% increased diabetes incidence, whereas ADIPOQ variants associated with adiponectin concentrations did not relate to diabetes risk.
Why the study?
Do common variants in ADIPOQ and its receptors associate with adiponectin concentrations and diabetes incidence in an obese/dysglycaemic population?
Cohort
Do common variants in ADIPOQ and its receptors associate with adiponectin concentrations and diabetes incidence in an obese/dysglycaemic population?
Effect estimate: ~18% increased incidence
While ADIPOQ SNPs associate with adiponectin concentrations, they do not relate to diabetes risk, whereas ADIPOR1 variants independently increase diabetes risk in an obese/dysglycaemic population.
No takes yet. Share an insight, caveat, or question.
ADIPOR1 variants should not yet guide diabetes prevention in obesity; leaves open receptor-specific pathways independent of adiponectin levels.
Mather et al. (2012) conducted a cohort in Type 2 diabetes mellitus. ADIPOQ, ADIPOR1, and ADIPOR2 single-nucleotide polymorphisms vs. Non-carriers of minor alleles was evaluated on Diabetes incidence (~18% increased incidence). Two ADIPOR1 SNPs were associated with an ~18% increased diabetes incidence, whereas ADIPOQ variants associated with adiponectin concentrations did not relate to diabetes risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: